Pfizer dials down its atirmociclib ambitions
The company is stepping back in second-line breast cancer.
Sutro calls time on folate
At long last luvelta-T is shelved, and Sutro seeks a new focus.
Arvinas’s degrader disappoints
The Pfizer-partnered vepdegestrant shows a benefit in ESR1 mutants, but not in all-comers.
Merck and Sanofi sound the alarm for ILT inhibition
Merck & Co gives up on Agenus, while Sanofi hands BND-22 back to Biond.
GSK and Hansoh press on despite Pfizer’s exit
A Chinese phase 3 trial of the partners’ B7-H4-targeting ADC has just begun.
A pivotal push from BeiGene
BGB-16673 and BGB-43395 will soon both be in phase 3 trials, BeiGene reveals.
FDA red and green lights: February 2025
Adcetris bags its eighth approval, while SpringWorks and Ono also feature.
Oric looks over its shoulder
Tough equity markets as well as competitor developments prompt a narrowed focus.
ASCO-GU – some backing for Pfizer's EZH2 plan
Phase 1 data give investors a benchmark for mevrometostat's pivotal Mevpro-1 trial.
